Re: Covid-19: Arthritis drug tocilizumab reduces deaths in hospitalised patients, study shows

Source: BMJ Comments - Category: General Medicine Source Type: forums

Related Links:

Lilly announced additional findings indicating that its rheumatoid arthritis drug, baricitinib, may improve the health of severe Covid-19 patients when used in combination with Gilead Science ’s antiviral drug remdesivir.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: Science /science Innovation /innovation Healthcare /healthcare Editors' Pick editors-pick Coronavirus technology alexknappblog Source Type: news
Abstract Since the first case reports in Wuhan, China, the SARS-CoV-2 has caused a pandemic and took lives of > 8,35,000 people globally. This single-stranded RNA virus uses Angiotensin-converting enzyme 2 (ACE2) as a receptor for entry into the host cell. Overexpression of ACE2 is mainly observed in hypertensive, diabetic and heart patients that make them prone to SARS-CoV-2 infection. Mitigations strategies were opted globally by the governments to minimize transmission of SARS-CoV-2 via the implementation of social distancing norms, wearing the facemasks, and spreading awareness using digital p...
Source: Molecular and Cellular Biochemistry - Category: Biochemistry Authors: Tags: Mol Cell Biochem Source Type: research
ConclusionAntiphospholipid antibodies were common in critically ill patients with COVID ‐19. Repeated testing demonstrating medium to high titers of aPLs and the number of aPL types a patient is positive for may help in identifying patients who are at risk of developing cerebral infarction. Antiphospholipid antibodies may be transient and disappear within a few weeks, but in genetica lly predisposed patients, COVID‐19 may trigger the development of an autoimmune condition similar to the antiphospholipid syndrome (APS), referred to as “COVID‐19–induced APS‐like syndrome.” Long‐term follow‐up of...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Brief Report Source Type: research
ConclusionsLack of availability of sound scientific knowledge inevitably lead unreliable news to spread over the population, preventing people to disentangle them form reliable information. Even if additional studies are needed to replicate and strengthen our results, these findings represent initial evidence to derive recommendations based on actual data for subjects with autoimmune diseases.
Source: Autoimmunity Highlights - Category: Allergy & Immunology Source Type: research
Just a few hours after revealing that he tested positive for COVID-19, U.S. President Donald Trump on Friday was helicoptered to Walter Reed Army Hospital, where he will be hospitalized for at least a few days “out of an abundance of caution,” the White House says; the First Lady, Melania Trump, has also tested positive. How the President of the United States is treated for COVID-19 will likely be very different from how the 7 million-plus other Americans who have contracted the disease were taken care of, at least in some ways. To start, before Trump was hospitalized, his physician Sean Conley revealed that th...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 UnitedWeRise20Disaster Source Type: news
ConclusionOur understanding of SARS –CoV‐2–related syndromes in the pediatric population continues to evolve. The guidance provided in this “living document” reflects currently available evidence, coupled with expert opinion, and will be revised as further evidence becomes available.
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Full Length Source Type: research
In medical school, I was charged with caring for Ms. R, a 47-year-old woman with type 2 diabetes, hypertension, and rheumatoid arthritis. She had been flagged as a high priority patient through the student-run free clinic (SRFC) and assigned to me for long-term follow-up. This signified seeing her during monthly check-ups, scheduling her appointments with […]Find jobs at  Careers by KevinMD.com.  Search thousands of physician, PA, NP, and CRNA jobs now.  Learn more.
Source: Kevin, M.D. - Medical Weblog - Category: General Medicine Authors: Tags: Conditions COVID-19 coronavirus Infectious Disease Source Type: blogs
Digital media&downloads Pain Relief Caused by SARS-CoV-2 Infection May Help Explain COVID-19 Spread New research shows SARS-CoV-2 promotes pain relief when it infects cells through a common protein receptor, neuropilin-1. The finding gives scientists a novel target for non-opioid pain therapeutics, while also offering an explanation for the unrelenting spread of COVID-19. Stacy Pigott Today University of Arizona Health SciencesKhanna_Raj_klh3067.jpg Doctoral student Lisa Boinon prepares buffers while Rajesh Khanna looks on. (Photo: Kris Hanning/University of Arizona Health Sciences)HealthCollege of Medicine - Tuc...
Source: The University of Arizona: Health - Category: Universities & Medical Training Authors: Source Type: research
Adalimumab could counter hyper-inflammation seen in severe coronavirus casesCoronavirus – latest updatesSee all our coronavirus coverageA commonly used arthritis drug is to be trialled with care home residents who have Covid, after it was observed that those taking it for their joint pains were less likely to end up in hospital with the virus.Older people in care homes, who often have some degree of dementia, tend not to do well in hospital, where they become more confused and may pick up infections. The trial will break new ground by giving the drug to people at care homes, where they can be supervised and monitored...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Coronavirus outbreak UK news Medical research Older people Social care Health NHS Drugs Infectious diseases Science Society Source Type: news
Nature Reviews Rheumatology, Published online: 30 September 2020; doi:10.1038/s41584-020-00521-xCardiac toxicity can be induced by hydroxychloroquine, especially when used in combination with azithromycin. Interest in hydroxychloroquine and azithromycin as potential therapies for COVID-19 has renewed concerns about the possible cardiovascular risk these drugs present to patients with rheumatoid arthritis.
Source: Nature Reviews Rheumatology - Category: Rheumatology Authors: Source Type: research
More News: Actemra | Arthritis | COVID-19 | General Medicine | Rheumatology | Study